MDNAF
Medicenna Therapeutics Corp.
Set alert
0.31 USD -0.04 -10.63%
0.32 Day range 0.33
0.237 52-week range 1.19
- YTD
- -53.99%
- 1 year
- -70.38%
- Open
- 0.33
- Prev close
- 0.348
- Mkt cap
- 28.71M
- Vol
- 7.50K
- Avg vol
- 43.53K
- EPS
- -0.16
- P/E
- 0.00
More statistics
- Low
- 0.32
- High
- 0.33
Financials — quick view
MDNAF Revenue — quarterly 0
MDNAF Net income — quarterly -2.86M
MDNAF EPS — quarterly -0.04
News
- Medicenna Reports Potent CD122 Blockade and Extended Survival with MDNA209 in Preclinical Models of Autoimmune Disease
- Medicenna Announces Results of Annual General and Special Meeting of Shareholders
- Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
- Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
- Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
- Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
- Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
- Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
- Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
- Medicenna Announces the Launch of a Marketed Public Offering of Securities
Your note
Sign in to keep a note on MDNAF — it syncs with the Stock Master app.